PTC Therapeutics, Inc.
http://www.ptcbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PTC Therapeutics, Inc.
US FDA Formal Dispute Resolution Guides Evolution Of Trials For CKD Complications, Pain
Ardelyx will add to FDA’s growing dispute resolution queue with plan to appeal tenapanor complete response letter; Avenue Therapeutics’ IV tramadol dispute resolution tops out with FDA plea for advisory committee advice.
Finance Watch: Evotec, LianBio, IO Biotech Launch IPOs, Bringing US Total To 101
Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq.
Autolus On The Rise After Big Backing From Blackstone
The cash injection comes as a potentially pivotal trial of Autolus's next-generation leukemia CAR-T therapy continues to enrol ahead of a readout in 2022.
Poseida’s Solid Tumor CAR-T Shows Early Promise, But Safety Will Be Closely Watched
Developing CAR-Ts against solid tumors that are both safe and effective is proving a huge technical challenge, but San Diego biotech Poseida believes it has made important progress.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Agilis Biotherapeutics, Inc.
- Censa Pharmaceuticals Inc.